Biomarkers in a Candian Memory Clinic (NCT06843109) | Clinical Trial Compass
By InvitationNot Applicable
Biomarkers in a Candian Memory Clinic
Canada100 participantsStarted 2024-06-11
Plain-language summary
This is a prospective, observational, case control study in a real-world cohort of patients referred by a primary care physician to a tertiary memory clinic for cognitive concerns. This study's main objective is to determine the effect of using standardized criteria (based on eligibility for disease modifying treatment (DMT)) to triage patients towards biological staging of disease with biomarker testing.
Who can participate
Age range
55 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Individual with MCI (if not yet diagnosed, individuals with amnestic changes in memory as shown on MoCA)
. MoCA score must be 18 to 28 inclusive
. Age 55 to 80 years inclusive
. Has a study partner that is willing to participate as a source of information and has approximately weekly contact with the subject (contact can be in-person, via telephone or electronic communication). The study partner must have sufficient contact such that the investigator feels the study partner can provide meaningful information about the subject's daily function.
. Group A - must have a clinical memory assessment appointment scheduled at Parkwood Institute within 18 months of baseline
. Group B - must have had a clinical memory assessment appointment at Parkwood Institute within 18 months of baseline
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is enrolling by invitation only — how would I or my family member actually get considered for an invitation, and is our memory clinic participating in this study?
2Since the trial is focused on testing whether it's even feasible to use cerebrospinal fluid (CSF) biomarkers in memory clinic decisions, does that mean the approach is still experimental rather than an established part of diagnosis, and how does that affect what we'd learn from participating?
3A CSF biomarker test involves a lumbar puncture to collect spinal fluid — can you walk me through what that procedure involves, what the risks are, and whether my current health situation makes it appropriate?
4If this study is mainly measuring feasibility rather than testing a treatment, what would participating actually mean for my care — would the biomarker results influence my diagnosis or treatment plan, or is the data primarily for research purposes?
5Are there standard diagnostic tools or blood-based biomarker tests already available at this clinic that might give us similar information about Alzheimer's disease without needing to join a research study?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Determine the feasibility of integrating a CSF biomarker into diagnostic decision making for AD.
Timeframe: through study completion, approximately 1 year
Trial details
NCT IDNCT06843109
SponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's